Correction to: Dose-related effects of ketamine for antidepressant-resistant symptoms of posttraumatic stress disorder in veterans and active duty military: a double-blind, randomized, placebo-controlled multi-center clinical trial (Neuropsychopharmacology, (2022), 47, 8, (1574-1581), 10.1038/s41386-022-01266-9)

Chadi G. Abdallah, John D. Roache, Ralitza Gueorguieva, Lynnette A. Averill, Stacey Young-McCaughan, Paulo R. Shiroma, Prerana Purohit, Antoinette Brundige, William Murff, Kyung Heup Ahn, Mohamed A. Sherif, Eric J. Baltutis, Mohini Ranganathan, Deepak D’Souza, Brenda Martini, Steven M. Southwick, Ismene L. Petrakis, Rebecca R. Burson, Kevin B. Guthmiller, Argelio L. López-RocaKarl A. Lautenschlager, John P. McCallin, Matthew B. Hoch, Alexandar Timchenko, Sergio E. Souza, Charles E. Bryant, Jim Mintz, Brett T. Litz, Douglas E Williamson, Terence M. Keane, Alan L Peterson, John H. Krystal

Research output: Contribution to journalComment/debatepeer-review

Abstract

In Table 1 of this article, the values in the row headed ‘CAPS-5’ have been corrected. They now read as shown below. The original article has been corrected.

Original languageEnglish (US)
Pages (from-to)1583-1584
Number of pages2
JournalNeuropsychopharmacology
Volume47
Issue number8
DOIs
StatePublished - Jul 2022

ASJC Scopus subject areas

  • Pharmacology
  • Psychiatry and Mental health

Fingerprint

Dive into the research topics of 'Correction to: Dose-related effects of ketamine for antidepressant-resistant symptoms of posttraumatic stress disorder in veterans and active duty military: a double-blind, randomized, placebo-controlled multi-center clinical trial (Neuropsychopharmacology, (2022), 47, 8, (1574-1581), 10.1038/s41386-022-01266-9)'. Together they form a unique fingerprint.

Cite this